TY  - CONF

T1  - Preclinical Investigation of Inhibition of the DNA Damage Response as a Targetted Therapy in Myeloproliferative Neoplasms Shows Synergism of ATR Inhibitors with Standard-of-Care Treatment

JO  - The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response

UR  - http://dx.doi.org/10.3390/iecc2021-09209

PY  - 2021/01/29

AU  - Ślusarczyk A

AU  - Bryant HE

AU  - Chen E

AU  - Hitchcock I

AU  - Zeidler M

AU  - Chantry A

AU  - Thomas S

ED  - 

DO  - DOI: 10.3390/iecc2021-09209

PB  - MDPI

VL  - 129

SP  - 17

EP  - 17

Y2  - 2024/12/22

ER  -